Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Pradaxa | Dabigatran etexilate | Thromboembolism (venous), prevention | Do not list | Complete | ||
Xarelto | Rivaroxaban | Thromboembolism (venous), prevention | List with clinical criteria and/or conditions | Complete | ||
Eliquis | Apixaban | Thromboembolic events prevention, (atrial fibrillation) | List with clinical criteria and/or conditions | Complete | ||
Revolade | Eltrombopag | Thrombocytopenia associated with chronic hepatitis c infection | List with criteria/condition | Complete | ||
Ledaga | chlormethine hydrochloride | T-cell lymphoma | Do not reimburse | Complete | ||
Atriance | nelarabine | T-cell acute lymphoblastic leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Rydapt | Midostaurin | Systemic Mastocytosis | Do not reimburse | Complete | ||
Benlysta | Belimumab | systemic lupus erythematosus | Do not reimburse | Complete | ||
Benlysta | Belimumab | Systemic lupus erythematosus | Do not list | Complete | ||
Saphnelo | anifrolumab | Systemic lupus erythematosus | Reimburse with clinical criteria and/or conditions | Complete |